Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

BDRX

Biodexa Pharmaceuticals Plc ADR

May 15 • 01:27PM ET

1.12

Dollar change +0.02
Percentage change 1.82	%

Healthcare • Biotechnology • United Kingdom • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-19.22	Insider Own	-	Shs Outstand	2.97M	Perf Week	12.00%
Market Cap	0.27M	Forward P/E	-	EPS next Y	-0.00	Insider Trans	-	Shs Float	-	Perf Month	30.16%
Income	-8.80M	PEG	-	EPS next Q	-0.00	Inst Own	38.73%	Short Float	-	Perf Quarter	-34.88%
Sales	0.47M	P/S	0.57	EPS this Y	91.79%	Inst Trans	-10.09%	Short Ratio	0.70	Perf Half Y	-52.34%
Book/sh	0.38	P/B	2.94	EPS next Y	15.41%	ROA	-87.62%	Short Interest	2.06M	Perf Year	-93.82%
Cash/sh	31.71	P/C	0.04	EPS next 5Y	-	ROE	-180.18%	52W Range	0.67 - 20.39	Perf YTD	-58.21%
Dividend Est.	-	P/FCF	-	EPS past 5Y	86.34%	ROI	-138.80%	52W High	-94.51%	Beta	1.50
Dividend TTM	-	Quick Ratio	1.26	Sales past 5Y	53.21%	Gross Margin	-	52W Low	67.16%	ATR (14)	0.15
Dividend Ex-Date	-	Current Ratio	1.26	EPS Y/Y TTM	99.06%	Oper. Margin	-2115.65%	RSI (14)	52.52	Volatility	10.59% 14.09%
Employees	21	Debt/Eq	0.10	Sales Y/Y TTM	-46.29%	Profit Margin	-1866.29%	Recom	1.00	Target Price	8.00
Option/Short	No / Yes	LT Debt/Eq	0.06	EPS Q/Q	99.66%	Payout	-	Rel Volume	0.07	Prev Close	1.10
Sales Surprise	-	EPS Surprise	0.00%	Sales Q/Q	-61.66%	Earnings	Apr 19 BMO	Avg Volume	2.95M	Price	1.12
SMA20	9.62%	SMA50	3.59%	SMA200	-62.02%	Trades		Volume	121,249	Change	1.82%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-08-24	Initiated	Ladenburg Thalmann	Buy	$8

Today 03:58AM	Posting of Annual Report & Notice of AGM - Total Voting Rights (GlobeNewswire)
May-09-24 08:00AM	Biodexa Looks To Prevent Or Delay The Worst Outcomes For Adolescents And Young Adults With Devastating Precancerous Condition (ACCESSWIRE)
Apr-30-24 11:52AM	Biodexa's Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa in Familial Adenomatous Polyposis to be Presented at Prestigious 2024 Digestive Disease Week Annual Meeting (GlobeNewswire) +15.27%
Apr-28-24 12:01PM	12 ChatGPT Penny Stock Picks Right Now (Insider Monkey)
Apr-26-24 03:18PM	Why Is Biodexa (BDRX) Up 70% Today? (InvestorPlace) +79.36%
08:30AM	Loading…
08:30AM	Biodexa Enters Into Exclusive License to eRapa , a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP) (GlobeNewswire)
Apr-19-24 08:00AM	Preliminary Results for the Year Ended 31 December 2023 (GlobeNewswire) -8.30%
Mar-28-24 11:22AM	Why Is Biodexa Pharmaceuticals (BDRX) Stock Up 106% Today? (InvestorPlace) +88.59%
08:15AM	Biodexa's MTX110 Shows Promise In Extending Life Expectancy Against Aggressive Brain Cancers (ACCESSWIRE)
Mar-01-24 08:00AM	Biodexa Takes Aim At Type 1 Diabetes With Innovative Drug Candidate Tolimidone (ACCESSWIRE) +7.09%
Feb-23-24 08:30AM	Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update (GlobeNewswire)
Feb-08-24 08:30AM	Biodexa Reports 12 Month Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma Patients (GlobeNewswire)
Feb-07-24 08:30AM	Biodexa Announces Allowance of U.S. Patent Covering Tolimidone (GlobeNewswire) -11.77%
Jan-22-24 08:30AM	Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024 (GlobeNewswire)
Dec-29-23 04:05AM	Biodexa Appoints Ann Merchant to the Board of Directors (GlobeNewswire)
04:00PM	Loading…
Dec-21-23 04:00PM	Biodexa Announces Closing Of $6.0 Million Underwritten Public Offering, Including Full Exercise Of Overallotment Option (GlobeNewswire)
Dec-19-23 08:42AM	Biodexa Announces Pricing of $5.2 Million Underwritten Public Offering (GlobeNewswire) -12.54%
Nov-27-23 09:00AM	Biodexa Enters Into Agreements to Acquire Exclusive Worldwide License to Tolimidone, a Phase II Ready Asset for Type 1 Diabetes (GlobeNewswire) +83.15%
Oct-03-23 08:30AM	Biodexa Completes Recruitment of Cohort A in Study of MTX110 in Patients with Recurrent Glioblastoma (GlobeNewswire)
Sep-29-23 04:30PM	Interim results for the six months ended 30 June 2023 (GlobeNewswire)
Sep-21-23 08:30AM	Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma at 2023 Annual European Association of Neuro-Oncology Meeting (EANO) (GlobeNewswire)
Jul-28-23 08:00AM	Biodexa Pharmaceuticals Launches New Corporate and Clinical Trials Websites (GlobeNewswire)
Jul-24-23 07:30AM	Biodexa Regain Compliance with NASDAQ Minimum Bid Price Requirement (GlobeNewswire) +15.18%
Jul-10-23 08:00AM	Completion of Enrolment and Treatment in the Phase 1 Study of MTX110 in the Treatment of Children with Newly Diagnosed Diffuse Midline Gliomas (DMGs) (GlobeNewswire)
Jul-06-23 04:30PM	Results of Appeal of Delisting Determination (GlobeNewswire)
08:15AM	Publication of Manuscript from the PNOC015 (a.k.a. MTD-201) Study in Patients with Diffuse Midline Glioma (DMG) (GlobeNewswire)
Jun-22-23 04:15PM	ADR Ratio Change (GlobeNewswire)
Jun-20-23 08:00AM	Appeal of Delisting Determination (GlobeNewswire) -12.11%
Jun-15-23 04:05PM	Receipt of NASDAQ Delisting Determination Plans to Appeal (GlobeNewswire)
Jun-14-23 08:30AM	Results of Annual General Meeting and General Meeting (GlobeNewswire) -6.78%
04:05PM	Loading…
May-26-23 04:05PM	Biodexa Pharmaceuticals PLC Announces Closing of $3.32 Million Registered Direct Offering (GlobeNewswire)
May-24-23 08:40AM	Biodexa Pharmaceuticals PLC Announces US$3.32 Million Registered Direct Offering (GlobeNewswire) -32.38%
May-22-23 04:15PM	Posting of Annual Report & Notice of AGM (GlobeNewswire)
May-18-23 08:30AM	Biodexa Pharmaceuticals Enters into Non-binding Letter of Intent for Proposed Acquisition of Varian Biopharmaceuticals (GlobeNewswire) -8.69%
Apr-28-23 04:30PM	Preliminary Results for the Year Ended 31 December 2022 (GlobeNewswire) -6.45%
Apr-20-23 01:30PM	Biodexa Pharmaceuticals PLC Announces Exercise of Pre-Funded Warrants & Issue of Equity (ACCESSWIRE)
Apr-11-23 08:15AM	Biodexa Pharmaceuticals PLC Announces Exercise of Pre-Funded Warrants & Issue of Equity (ACCESSWIRE) +6.49%
Apr-06-23 06:33AM	Biodexa Pharmaceuticals PLC Announces Exercise of Pre-Funded Warrants & Issue of Equity (ACCESSWIRE) -10.32%
Apr-03-23 08:00AM	Biodexa Pharmaceuticals PLC Announces Issue of Pre-Funded Warrants (ACCESSWIRE) -23.08%
Mar-30-23 06:20AM	Biodexa Pharmaceuticals PLC Announces Exercise of Warrants and Issue of Equity (ACCESSWIRE) -11.24%

Biodexa Pharmaceuticals Plc is a drug delivery technology company. It is focused on the research and development of medicines for rare cancers, via both in-house programs as well as partnered programs. The firm's proprietary platform drug delivery technologies are Q-Sphera platform is a disruptive polymer microsphere technology, which is used for sustained release at the microscale to prolong and control the release of therapeutics over an extended period of time from weeks to months; Midasolve platform is an innovative nano saccharide technology, which is used to dissolve drugs at the nanoscale so that they can be administered in liquid form directly and locally into tumors; Midacore platform is an edge gold nanoparticle technology, which is used for targeting sites of disease at the nanoscale. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BDRX

Biodexa Pharmaceuticals Plc ADR

Upgrade your FINVIZ experience